Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) announced publication of six patents in Hong Kong on March 17, 2026 covering proprietary combination therapies that integrate Palmitoylethanolamide (PEA) with six psychedelic compounds.
The patents protect formulations combining PEA with MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT, and reflect a sourcing partnership with NeuroThera Labs. The company describes these combinations as intended to enhance therapeutic potential, safety, tolerability, and neuroplasticity profiles for mental health and neurological indications.
Positive
- Publication of 6 patents in Hong Kong on March 17, 2026
- Patents cover PEA combinations with six psychedelic compounds
- Declared sourcing partnership with NeuroThera Labs for PEA
Negative
- Company remains clinical-stage with no approved commercial products
- IP publication limited to Hong Kong (geographic scope disclosed)
News Market Reaction – CMND
In the Mar 17 session, CMND gained 1.35%, reflecting a mild positive market reaction. Argus tracked a peak move of +11.3% during that session. Argus tracked a trough of -24.3% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.5x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | HK depression patent | Positive | -5.9% | Filed Hong Kong patent for MEAI‑PEA combo targeting major depressive disorder. |
| Mar 11 | Trial cohort enrollment | Positive | -6.3% | Advanced recruitment for CMND‑100 Phase I/IIa Cohort 3 after positive topline data. |
| Mar 10 | Weight loss patent | Positive | -2.0% | Published PCT patent for MEAI‑PEA therapy targeting weight loss and MASLD. |
| Mar 04 | DSMB trial greenlight | Positive | -4.8% | DSMB approved progression to 80 mg Cohort 3 in CMND‑100 AUD trial. |
| Feb 19 | Weight-loss spotlight | Positive | +4.2% | Promotional review highlighting MEAI and GLP‑1-related weight‑loss potential and IP. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and IP developments have often been followed by negative price reactions, suggesting a pattern of selling into good news.
Over the past month, Clearmind reported multiple positive developments, including DSMB approvals to advance its CMND-100 Phase I/IIa trial and new patent activity in Hong Kong and internationally for MEAI-PEA combination therapies in depression, weight loss, and MASLD. Despite these milestones, the stock frequently declined after such announcements, with four of the last five news events followed by negative moves. Today’s publication of six Hong Kong patents extends this IP-building trend but arrives against a backdrop of persistent price weakness and prior selling into similar news.
Key Terms
palmitoylethanolamide (pea) medical
3,4-methylenedioxymethamphetamine (mdma) medical
lysergic acid diethylamide (lsd) medical
ketamine medical
ibogaine medical
psilocybin medical
n,n-dimethyltryptamine (dmt) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, Canada, March 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of six patents by the Intellectual Property Department in Hong Kong. These patents cover proprietary combination therapies integrating Palmitoylethanolamide (PEA), sourced through the Company's partnership with NeuroThera Labs Inc. (TSXV: NTLX), with leading classic and innovative psychedelic compounds.
The published patents protect innovative synergistic formulations combining PEA with each of the following: 3,4-Methylenedioxymethamphetamine (MDMA), Lysergic Acid Diethylamide (LSD), Ketamine, Ibogaine, Psilocybin, and N,N-Dimethyltryptamine (DMT). These novel combinations aim to enhance therapeutic potential while potentially improving safety, tolerability, and neuroplasticity profiles for various mental health and neurological indications.
"We continue to expand our global IP portfolio and taking steps forward in protecting our innovative approach to psychedelic-based combination therapies," said Adi Zuloff-Shani, CEO of Clearmind Medicine. "By strategically combining PEA from our valued partners at NeuroThera with well-characterized psychedelics such as MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT, we continue to build a robust pipeline of next-generation candidates designed to address unmet needs in mental health and beyond.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses continuing to expand its global IP portfolio and taking steps forward in protecting its innovative approach to psychedelic-based combination therapies and continuing to build a robust pipeline of next-generation candidates designed to address unmet needs in mental health and beyond. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
